JWH-145

JWH-145

JWH-145 is a synthetic cannabinoid from the JWH series. It was developed by the team of John W. Huffman at Clemson University. It is a research chemical that acts as a potent agonist for the cannabinoid receptors.

Chemistry

JWH-145 is part of the JWH series of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids like JWH-018 and JWH-073. The chemical formula of JWH-145 is C24H23NO. It is a complex molecule with multiple functional groups, including a naphthoyl group, a cyclohexylmethyl group, and a nitro group.

Pharmacology

JWH-145 acts as a potent agonist for the cannabinoid receptors, with a particular affinity for the CB1 receptor. The CB1 receptor is primarily found in the brain and is responsible for the psychoactive effects of cannabinoids. JWH-145 binds to this receptor and mimics the effects of naturally occurring cannabinoids, such as delta-9-tetrahydrocannabinol (THC), the active ingredient in cannabis.

Effects

The effects of JWH-145 are similar to those of other synthetic cannabinoids and include euphoria, relaxation, and altered perception. However, due to its potency, the use of JWH-145 can also lead to adverse effects such as anxiety, paranoia, and psychosis. It is worth noting that the effects can vary greatly between individuals, and can be influenced by factors such as dose, route of administration, and individual susceptibility.

Legal Status

The legal status of JWH-145 varies by country. In many places, it is classified as a controlled substance due to its potential for abuse and the health risks associated with its use. In the United States, JWH-145 is a Schedule I controlled substance, making it illegal to manufacture, distribute, or possess.

See Also

• Synthetic cannabinoids
• JWH series
• Cannabinoid receptors
• John W. Huffman

This article is a stub related to pharmacology. You can help WikiMD by expanding it!